RNA - Avidity Biosciences  - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RNA is currently covered by 11 analysts with an average price target of $63.98. This is a potential upside of $33.14 (107.46%) from yesterday's end of day stock price of $30.84.

Avidity Biosciences 's activity chart (see below) currently has 26 price targets and 64 ratings on display. The stock rating distribution of RNA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 43.73% with an average time for these price targets to be met of 295.42 days.

Highest price target for RNA is $96, Lowest price target is $53, average price target is $62.18.

Most recent stock forecast was given by JOSEPH STRINGER from NEEDHAM on 09-Apr-2025. First documented stock forecast 07-Jul-2020.

Currently out of the existing stock ratings of RNA, 44 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$60

$29.16 (94.55%)

$60

18 days ago
(09-Apr-2025)

11/16 (68.75%)

$35.2 (141.94%)

246

Buy

$72

$41.16 (133.46%)

$72

1 months 9 days ago
(18-Mar-2025)

0/4 (0%)

$41.52 (136.22%)

Buy

$65

$34.16 (110.77%)

$65

1 months 10 days ago
(17-Mar-2025)

8/11 (72.73%)

$31.17 (92.14%)

299

Buy

$70

$39.16 (126.98%)

$48

1 months 14 days ago
(13-Mar-2025)

2/4 (50%)

$37.87 (117.86%)

44

Buy

$67

$36.16 (117.25%)

$67

3 months 6 days ago
(21-Jan-2025)

0/2 (0%)

$36.16 (117.25%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RNA (Avidity Biosciences ) average time for price targets to be met?

On average it took 295.42 days on average for the stock forecasts to be realized with a an average price target met ratio 43.73

Which analyst has the current highest performing score on RNA (Avidity Biosciences ) with a proven track record?

JOSEPH STRINGER

Which analyst has the most public recommendations on RNA (Avidity Biosciences )?

Joseph Stringer works at NEEDHAM and has 3 price targets and 5 ratings on RNA

Which analyst is the currently most bullish on RNA (Avidity Biosciences )?

Eric Schmidt with highest potential upside - $65.16

Which analyst is the currently most reserved on RNA (Avidity Biosciences )?

Joseph Schwartz with lowest potential downside - -$12.84

Avidity Biosciences  in the News

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO, April 8, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?